Delcath Systems Inc
Veridion Score
BETAMEDIUM CONF · 5/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is DCTH moving today?
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
DCTH overview
Related filings and maps
Congress activity in DCTH
No receipt-qualified Congressional disclosure is present for DCTH in the cached public ledger.
DCTH contract awards, year to date.
Public federal awards linked to this ticker.
DCTH lobbying filings, year to date.
Registered lobbying filings matched to Delcath Systems Inc.